血液分析装置および試薬市場規模、シェア、動向、2031年までの世界予測

世界の血液分析装置および試薬市場は、2026年の75億7,000万米ドルから2031年には103億3,000万米ドルに成長し、予測期間中の年平均成長率（CAGR）は6.4%に達するとMarketsandMarketsでは予測しています。血液分析装置および試薬の技術革新は、今後数年間の市場成長の主要な推進力になると予想されます。しかしながら、血液分析装置および試薬の高価格、新興国における熟練専門家の不足、そしてこれらの地域における高度な血液分析機器の普及の遅れは、血液分析装置および試薬市場の成長を阻害する可能性があります。

調査概要

本レポートは、血液分析装置および試薬市場を、製品・サービス、価格帯、用途、エンドユーザー、地域別に分析しています。また、市場成長の促進要因、市場における機会と課題、そして市場リーダーの競争環境についても詳細に解説しています。さらに、個々の成長傾向に基づいてマイクロ市場を分析し、5つの主要地域（および各地域内の各国）における市場セグメントの収益予測を提供しています。

本レポートを購入する理由

本レポートは、既存企業だけでなく新規参入企業や中小企業にとっても、市場の動向を把握し、より大きな市場シェアを獲得するための有効な手段となります。本レポートを購入した企業は、以下の戦略のいずれか、または複数の戦略を組み合わせて、市場での存在感を強化することができます。

本レポートは、以下のポイントに関する洞察を提供します。

• 造影剤市場の成長に影響を与える主要な推進要因（診断精度向上と血液分析ワークフロー最適化のためのAI技術の急速な統合、血液分析装置の利用拡大を支える高度なパラメータと多機能性、初回検査成功率と試薬使用量削減を実現する、手頃な価格で効率的な検査へのニーズの高まり）、阻害要因（高価な高度血液分析装置が医療機関への導入を阻害していること、異常細胞識別におけるデジタル形態分析装置の精度の限界）、機会（高度な細胞分析と希少細胞検出機能を提供するAIベースの遠隔血液診断ソリューションと精密診断の利用拡大）、および課題（次世代血液分析装置の登場によるデータ管理と分析の複雑化、血液学ワークフロー効率に影響を与える検査室不足）の分析。
• 製品開発／イノベーション：血液分析装置および試薬市場における今後の技術、研究開発活動、新製品・新サービスの発売に関する詳細な洞察。
• 市場開発：収益性の高い市場に関する包括的な情報。血液分析装置および試薬市場を様々な地域にわたって分析します。
• 市場の多様化：血液分析装置および試薬市場における新製品・サービス、未開拓地域、最新動向、投資に関する包括的な情報を提供します。
• 競合分析：主要企業の市場シェア、成長戦略、サービス提供内容を詳細に分析します。

Report Description

The global hematology analyzers and reagents market is projected to reach USD 10.33 billion by 2031 from USD 7.57 billion in 2026, growing at a CAGR of 6.4% during the forecast period. Advancements in hematology analyzers and reagents are expected to be a primary driver of market growth in the coming years. However, the high costs of hematology analyzers and reagents, the shortage of skilled experts in emerging nations, and the slow adoption of advanced hematology devices in these regions could hinder growth in the hematology analyzers and reagents market.

“The hematology products and services segment held the largest share of the market in 2025.”

The global market for hematology analyzers and reagents, by product and service, is segmented into hematology products & services, hemostasis products & services, and immunohematology products & services. Hematology products & services hold a dominant position in the global market for hematology analyzers and reagents. This segment is further divided into: instruments, reagents, consumables, and services. Factors driving growth include higher test volumes, rising prevalence of hematological conditions, and technological advancements such as the introduction of five- and six-part differential analyzers, flow cytometry, and artificial intelligence.

“The low-range hematology analyzers segment held the largest share of the market in 2025.”

Based on price range, the hematology analyzers and reagents market is segmented into high-range hematology analyzers, mid-range hematology analyzers, and low-range hematology analyzers.  It is anticipated that the market will be led by the low-range hematology analyzers segment throughout the forecast period. The anticipation of the dominance of the low-range hematology analyzer segment stems from its cost-effectiveness and ability to perform well in limited-resource environments, such as small labs and diagnostic centers. They come with a 3-part differential, small in size, smaller sample volumes, and are easy to operate.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18%, and Others–55%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

The prominent players in the hematology analyzers and reagents market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Diatron (Hungary), Drew Scientific (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Horiba Ltd. (Japan), Nihon Kohden Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BioSystems (Spain), and QuidelOrtho Corporation (US), among others.

Research Coverage

This report studies the hematology analyzers and reagents market based on product and service, price range, application, end user, and region. It also covers the factors driving market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape for market leaders. Furthermore, the report analyzes micro markets by their individual growth trends and forecasts revenue for the market segments across five main regions (and the respective countries within these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.

This report provides insights into the following pointers:

• Analysis of key drivers (rapid integration of AI technology for increased accuracy of diagnosis and optimized hematology analysis workflows, advanced parameters and multi-functionality behind increasing use of hematology analyzers, growing requirements for affordable and efficient tests with first-pass yield and less reagents usage), restraints (expensive advanced hematology analyzer instruments hampering their implementation in healthcare institutions and limited accuracy of digital morphology analyzers in identifying abnormal cells), opportunities (expanding use of AI-based telehematology solutions and precision diagnostics offering advanced cell analysis and rare cell detection capabilities), and challenges (Increased complexity of data management and analysis due to the advent of next-generation hematology analyzers and laboratory shortages affecting workflow efficiency of hematology) influencing the growth of the contrast media market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in hematology analyzers and reagents market
• Market Development: Comprehensive information about lucrative markets–the report analyses the hematology analyzers and reagents market across varied regions
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the hematology analyzers and reagents market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players

Table of Contents

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.3 STUDY SCOPE 27
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 27
1.3.2 INCLUSIONS AND EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 30
1.4 CURRENCY CONSIDERED 30
1.5 STAKEHOLDERS 30
1.6 SUMMARY OF CHANGES 31
2 EXECUTIVE SUMMARY 33
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 33
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 35
2.3 DISRUPTIVE TRENDS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 36
2.4 HIGH-GROWTH SEGMENTS 37
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 38
3 PREMIUM INSIGHTS 39
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 39
3.2 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION 40
3.3 HEMATOLOGY ANALYZERS AND REAGENTS MARKET IN ASIA PACIFIC, BY END USER AND COUNTRY 41
3.4 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY GEOGRAPHY 42
4 MARKET OVERVIEW 43
4.1 INTRODUCTION 43
4.2 MARKET DYNAMICS 43
4.2.1 DRIVERS 44
4.2.1.1 Rapid integration of AI to enhance diagnostic accuracy and optimize hematology workflows 44
4.2.1.2 Growing preference for high-parameter and multi-functional testing 45
4.2.1.3 Mounting demand for cost-efficient hematology analyzers 46
4.2.2 RESTRAINTS 46
4.2.2.1 High cost of advanced hematology analyzers 46
4.2.2.2 Limited accuracy of digital morphology analyzers in detecting rare and complex cell abnormalities 47

4.2.3 OPPORTUNITIES 47
4.2.3.1 Expansion of AI-enabled tele-hematology and remote diagnostics 47
4.2.3.2 Adoption of precision diagnostics enabling advanced cell profiling, rare cell detection, and early disease identification 48
4.2.4 CHALLENGES 49
4.2.4.1 Complexity in managing and interpreting data generated by next-generation hematology analyzers 49
4.2.4.2 Shortage of laboratory workforce 49
4.3 UNMET NEEDS 50
4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 50
5 INDUSTRY TRENDS 52
5.1 PORTER’S FIVE FORCES ANALYSIS 52
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 53
5.1.2 BARGAINING POWER OF BUYERS 53
5.1.3 BARGAINING POWER OF SUPPLIERS 53
5.1.4 THREAT OF NEW ENTRANTS 53
5.1.5 THREAT OF SUBSTITUTES 53
5.2 MACROECONOMIC OUTLOOK 54
5.2.1 INTRODUCTION 54
5.2.2 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 54
5.2.3 MACROECONOMIC OUTLOOK FOR EUROPE 54
5.2.4 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 55
5.2.5 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 55
5.2.6 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 56
5.2.7 TRENDS IN GLOBAL IN-VITRO DIAGNOSTICS (IVD) INDUSTRY 56
5.2.8 TRENDS IN GLOBAL POINT-OF-CARE (POC) DIAGNOSTICS INDUSTRY 56
5.3 VALUE CHAIN ANALYSIS 57
5.4 ECOSYSTEM ANALYSIS 58
5.5 PRICING ANALYSIS 59
5.5.1 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023–2025 60
5.5.2 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS,
BY PRICE RANGE, 2025 62
5.6 TRADE DATA ANALYSIS 63
5.6.1 IMPORT DATA (HS CODE 902780) 63
5.6.2 EXPORT DATA (HS CODE 902780) 64
5.7 KEY CONFERENCES AND EVENTS, 2026–2027 65
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66
5.9 INVESTMENT AND FUNDING SCENARIO 67

5.10 CASE STUDY ANALYSIS 68
5.10.1 DETECTION OF ABNORMAL WBC POPULATIONS IN HIGH WBC COUNT CASES USING XN-SERIES AUTOMATED HEMATOLOGY ANALYZER 68
5.10.2 MONITORING AND DETECTION OF ACUTE MYELOBLASTIC LEUKEMIA
(AML-M1) USING ADVANCED HEMATOLOGY ANALYZERS 69
5.10.3 DETECTION OF MICROCYTIC ANEMIA WITH THROMBOCYTOSIS THROUGH ADVANCED SCATTERGRAM ANALYSIS 69
5.11 IMPACT OF US TARIFFS – HEMATOLOGY ANALYZERS AND REAGENTS MARKET 70
5.11.1 INTRODUCTION 70
5.11.2 KEY TARIFF RATES 70
5.11.3 PRICE IMPACT ANALYSIS 70
5.11.4 IMPACT ON COUNTRIES/REGIONS 71
5.11.4.1 US 71
5.11.4.2 Europe 71
5.11.4.3 Asia Pacific 72
5.11.5 IMPACT ON END USERS 72
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 73
6.1 KEY TECHNOLOGIES 73
6.1.1 FLOW CYTOMETRY 73
6.1.2 DIGITAL MORPHOLOGY ANALYZERS 73
6.1.3 MICROFLUIDICS 74
6.2 COMPLEMENTARY TECHNOLOGIES 74
6.2.1 LABORATORY INFORMATION SYSTEMS 74
6.2.2 CLOUD & REMOTE DIAGNOSTICS 74
6.3 PATENT ANALYSIS 75
6.4 FUTURE APPLICATIONS 77
6.5 IMPACT OF AI/GEN AI ON HEMATOLOGY ANALYZERS AND REAGENTS MARKET 77
6.5.1 TOP USE CASES AND MARKET POTENTIAL 78
6.5.2 BEST PRACTICES FOLLOWED BY COMPANIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 79
6.5.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 80
6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS 80
6.5.5 CLIENTS’ READINESS TO ADOPT AI/GEN AI-INTEGRATED HEMATOLOGY ANALYZERS AND REAGENTS 81
6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 81
7 REGULATORY LANDSCAPE 83
7.1 REGIONAL REGULATIONS AND COMPLIANCE 83
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
7.1.2 REGULATORY TRENDS 86
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 90
8.1 DECISION-MAKING PROCESS 90
8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA 91
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
8.2.2 BUYING CRITERIA 92
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 93
8.4 UNMET NEEDS OF VARIOUS END USERS 94
9 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE 97
9.1 INTRODUCTION 98
9.2 LOW-RANGE HEMATOLOGY ANALYZERS 99
9.2.1 LOW OPERATING EXPENSES TO ACCELERATE SEGMENTAL GROWTH 99
9.3 HIGH-RANGE HEMATOLOGY ANALYZERS 100
9.3.1 HIGH ACCURACY AND MULTI-PARAMETER APPROACH TO FUEL
SEGMENTAL GROWTH 100
9.4 MID-RANGE HEMATOLOGY ANALYZERS 101
9.4.1 INTEGRATION WITH QUALITY CONTROL SOFTWARE TO SUPPORT
SEGMENTAL GROWTH 101
10 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE 103
10.1 INTRODUCTION 104
10.2 STANDALONE ANALYZERS 104
10.2.1 INCREASING DEMAND FOR HIGH-THROUGHPUT AND AUTOMATED LABORATORY WORKFLOWS TO FOSTER SEGMENTAL GROWTH 104
10.3 POINT-OF-CARE ANALYZERS 105
10.3.1 SHIFTING PREFERENCE TOWARD DECENTRALIZED AND RAPID DIAGNOSTICS TO EXPEDITE SEGMENTAL GROWTH 105
11 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE 107
11.1 INTRODUCTION 108
11.2 HEMATOLOGY PRODUCTS & SERVICES 108
11.2.1 REAGENTS & CONSUMABLES 110
11.2.1.1 Hematology reagents 111
11.2.1.1.1 Growing preference for rental business models to drive market 111
11.2.1.2 Hematology consumables 112
11.2.1.2.1 Requirement for accurate and efficient blood analysis in laboratory workflows to spur demand 112
11.2.1.3 Controls & calibrators 113
11.2.1.3.1 Ability to monitor multiple parameters to boost segmental growth 113

11.2.1.4 Slide stainers & makers 114
11.2.1.4.1 Detailed visualization of cellular morphology to augment segmental growth 114
11.2.2 INSTRUMENTS 115
11.2.2.1 5-part & 6-part fully automated hematology analyzers 117
11.2.2.1.1 Identification and classification of WBCs to drive market 117
11.2.2.2 3-part fully automated hematology analyzers 118
11.2.2.2.1 Low maintenance costs to contribute to segmental growth 118
11.2.2.3 Point-of-care & semi-automated testing hematology analyzers 119
11.2.2.3.1 Shift toward decentralized, rapid, and multi-parameter hematology testing to spur demand 119
11.2.3 SERVICES 120
11.2.3.1 High adoption of diagnostic techniques to boost segmental growth 120
11.3 HEMOSTASIS PRODUCTS & SERVICES 121
11.3.1 HEMOSTASIS REAGENTS & CONSUMABLES 122
11.3.1.1 Expanding use in comprehensive coagulation testing and specialized diagnostics to fuel segmental growth 122
11.3.2 HEMOSTASIS INSTRUMENTS 122
11.3.2.1 High productivity with low complexities to drive market 122
11.3.3 HEMOSTASIS SERVICES 123
11.3.3.1 Advancements in hemostasis diagnostic techniques to support segmental growth 123
11.4 IMMUNOHEMATOLOGY PRODUCTS & SERVICES 124
11.4.1 IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES 125
11.4.1.1 Use to ensure accurate transfusion testing and enhance blood safety to bolster segmental growth 125
11.4.2 IMMUNOHEMATOLOGY INSTRUMENTS 126
11.4.2.1 Growing automation in immunohematology labs to foster segmental growth 126
11.4.3 SERVICES 127
11.4.3.1 Provision of customer-focused care to support segmental growth 127
12 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION 128
12.1 INTRODUCTION 129
12.2 HEMORRHAGIC CONDITIONS 129
12.2.1 INCREASING DEMAND FOR DECENTRALIZED AND FREQUENT MONITORING TO EXPEDITE SEGMENTAL GROWTH 129
12.3 INFECTIOUS DISEASES 130
12.3.1 NEED FOR RAPID SCREENING TO ACCELERATE SEGMENTAL GROWTH 130
12.4 IMMUNE SYSTEM DISORDERS 131
12.4.1 FOCUS ON ADVANCED BLOOD PROFILING TO FACILITATE SEGMENTAL GROWTH 131
12.5 BLOOD CANCER 132
12.5.1 ABILITY TO IDENTIFY ABNORMAL BLOOD CELLS AND MORPHOLOGICAL ABNORMALITIES TO DRIVE MARKET 132
12.6 ANEMIA 134
12.6.1 SHIFT TOWARD ADVANCED RBC PARAMETER ANALYSIS TO BOOST SEGMENTAL GROWTH 134
12.7 OTHER APPLICATIONS 135
13 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER 136
13.1 INTRODUCTION 137
13.2 COMMERCIAL SERVICE PROVIDERS 137
13.2.1 HIGH EMPHASIS ON HIGH-VOLUME ROUTINE TESTING, PREVENTIVE SCREENING, AND ADVANCED DIAGNOSTICS TO DRIVE MARKET 137
13.3 HOSPITAL LABORATORIES 139
13.3.1 RISING NEED FOR REAL-TIME PATIENT DIAGNOSIS AND EMERGENCY TESTING TO EXPEDITE SEGMENTAL GROWTH 139
13.4 GOVERNMENT REFERENCE LABORATORIES 140
13.4.1 INCREASING NEED FOR LARGE-SCALE DISEASE SURVEILLANCE, SCREENING, AND DIAGNOSTIC STANDARDIZATION TO SPUR DEMAND 140
13.5 RESEARCH & ACADEMIC INSTITUTES 141
13.5.1 GROWING FOCUS ON ADVANCED DISEASE PROFILING, BIOMARKER DISCOVERY, AND TRANSLATIONAL RESEARCH TO BOOST SEGMENTAL GROWTH 141
14 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION 142
14.1 INTRODUCTION 143
14.2 NORTH AMERICA 143
14.2.1 US 149
14.2.1.1 Rising incidence of anemia and hemophilia to drive market 149
14.2.2 CANADA 150
14.2.2.1 Mounting demand for accurate blood diagnostics to bolster market growth 150
14.3 EUROPE 151
14.3.1 GERMANY 156
14.3.1.1 Increasing prevalence of anemia to contribute to market growth 156
14.3.2 FRANCE 157
14.3.2.1 Rising adoption of automated and high-throughput hematology analyzers to support market growth 157
14.3.3 UK 158
14.3.3.1 High incidence of blood-related disorders to expedite market growth 158
14.3.4 ITALY 159
14.3.4.1 Growing acceptance of hematology-based diagnostics to boost market growth 159
14.3.5 SPAIN 159
14.3.5.1 Rising preference for automated and high-throughput hematology systems to augment market growth 159
14.3.6 REST OF EUROPE 160

14.4 ASIA PACIFIC 161
14.4.1 CHINA 167
14.4.1.1 Large target patient population to expedite market growth 167
14.4.2 JAPAN 168
14.4.2.1 Rising cases of influenza to support market growth 168
14.4.3 INDIA 169
14.4.3.1 Government-led procurement initiatives and expanding diagnostic infrastructure to fuel market growth 169
14.4.4 AUSTRALIA 170
14.4.4.1 Increasing prevalence of celiac disease to drive market 170
14.4.5 SOUTH KOREA 171
14.4.5.1 Strong focus on advanced diagnostics and automation to contribute to market growth 171
14.4.6 REST OF ASIA PACIFIC 171
14.5 LATIN AMERICA 172
14.5.1 BRAZIL 177
14.5.1.1 Increasing burden of anemia and infectious diseases to expedite market growth 177
14.5.2 MEXICO 178
14.5.2.1 Mounting demand for diagnostic testing to accelerate market growth 178
14.5.3 REST OF LATIN AMERICA 179
14.6 MIDDLE EAST & AFRICA 179
14.6.1 HIGH DISEASE AWARENESS, IMPROVING HEALTHCARE INFRASTRUCTURE, AND ADVANCED TREATMENT OPTIONS TO DRIVE MARKET 179
14.6.2 GCC COUNTRIES 184
14.6.3 REST OF MIDDLE EAST & AFRICA 185
15 COMPETITIVE LANDSCAPE 186
15.1 OVERVIEW 186
15.2 KEY PLAYERS COMPETITIVE STRATEGIES/RIGHT TO WIN, 2022–2026 186
15.3 REVENUE ANALYSIS, 2021–2025 188
15.4 MARKET SHARE ANALYSIS, 2025 189
15.5 MARKET RANKING, 2025 192
15.6 COMPANY VALUATION AND FINANCIAL METRICS 192
15.7 PRODUCT COMPARISON 193
15.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 194
15.8.1 STARS 194
15.8.2 EMERGING LEADERS 194
15.8.3 PERVASIVE PLAYERS 194
15.8.4 PARTICIPANTS 194
15.8.5 COMPETITIVE FOOTPRINT: KEY PLAYERS, 2025 196
15.8.5.1 Company footprint 196
15.8.5.2 Region footprint 197
15.8.5.3 Product & service footprint 198
15.8.5.4 Application footprint 199
15.8.5.5 End user footprint 200
15.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 201
15.9.1 PROGRESSIVE COMPANIES 201
15.9.2 RESPONSIVE COMPANIES 201
15.9.3 DYNAMIC COMPANIES 201
15.9.4 STARTING BLOCKS 201
15.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 203
15.9.5.1 Detailed list of key startups/SMEs 203
15.9.5.2 Competitive benchmarking of key startups/SMEs 204
15.10 COMPETITIVE SCENARIO 205
15.10.1 PRODUCT LAUNCHES AND APPROVALS 205
15.10.2 DEALS 206
15.10.3 EXPANSIONS 206
16 COMPANY PROFILES 208
16.1 KEY PLAYERS 208
16.1.1 SYSMEX CORPORATION 208
16.1.1.1 Business overview 208
16.1.1.2 Products offered 209
16.1.1.3 Recent developments 211
16.1.1.3.1 Deals 211
16.1.1.3.2 Expansions 212
16.1.1.4 MnM view 213
16.1.1.4.1 Right to win 213
16.1.1.4.2 Strategic choices 213
16.1.1.4.3 Weaknesses and competitive threats 213
16.1.2 ABBOTT 214
16.1.2.1 Business overview 214
16.1.2.2 Products offered 215
16.1.2.3 Recent developments 216
16.1.2.3.1 Product launches and approvals 216
16.1.2.4 MnM view 217
16.1.2.4.1 Right to win 217
16.1.2.4.2 Strategic choices 217
16.1.2.4.3 Weaknesses and competitive threats 217

16.1.3 DANAHER CORPORATION 218
16.1.3.1 Business overview 218
16.1.3.2 Products offered 219
16.1.3.3 Recent developments 220
16.1.3.3.1 Deals 220
16.1.3.4 MnM view 220
16.1.3.4.1 Right to win 220
16.1.3.4.2 Strategic choices 221
16.1.3.4.3 Weaknesses and competitive threats 221
16.1.4 SIEMENS HEALTHINEERS AG 222
16.1.4.1 Business overview 222
16.1.4.2 Products offered 223
16.1.4.3 Recent developments 225
16.1.4.3.1 Product launches and approvals 225
16.1.4.3.2 Deals 225
16.1.4.4 MnM view 225
16.1.4.4.1 Right to win 225
16.1.4.4.2 Strategic choices 225
16.1.4.4.3 Weaknesses and competitive threats 226
16.1.5 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 227
16.1.5.1 Business overview 227
16.1.5.2 Products offered 228
16.1.5.3 Recent developments 229
16.1.5.3.1 Product launches and approvals 229
16.1.5.4 MnM view 229
16.1.5.4.1 Right to win 229
16.1.5.4.2 Strategic choices 229
16.1.5.4.3 Weaknesses and competitive threats 229
16.1.6 DIATRON 230
16.1.6.1 Business overview 230
16.1.6.2 Products offered 230
16.1.6.3 Recent developments 231
16.1.6.3.1 Expansions 231
16.1.7 DREW SCIENTIFIC 232
16.1.7.1 Business overview 232
16.1.7.2 Products offered 232
16.1.8 BIO-RAD LABORATORIES, INC. 233
16.1.8.1 Business overview 233
16.1.8.2 Products offered 234
16.1.8.3 Recent developments 235
16.1.8.3.1 Product launches and approvals 235

16.1.9 HORIBA 236
16.1.9.1 Business overview 236
16.1.9.2 Products offered 237
16.1.9.3 Recent developments 239
16.1.9.3.1 Product launches and approvals 239
16.1.10 NIHON KOHDEN CORPORATION 240
16.1.10.1 Business overview 240
16.1.10.2 Products offered 241
16.1.10.3 Recent developments 242
16.1.10.3.1 Expansions 242
16.1.11 EKF DIAGNOSTICS HOLDINGS PLC 243
16.1.11.1 Business overview 243
16.1.11.2 Products offered 244
16.1.11.3 Recent developments 245
16.1.11.3.1 Product launches and approvals 245
16.1.12 BOULE 246
16.1.12.1 Business overview 246
16.1.12.2 Products offered 247
16.1.12.3 Recent developments 248
16.1.12.3.1 Product launches and approvals 248
16.1.12.3.2 Deals 248
16.1.13 F. HOFFMANN-LA ROCHE LTD 249
16.1.13.1 Business overview 249
16.1.13.2 Products offered 250
16.1.13.3 Recent developments 251
16.1.13.3.1 Deals 251
16.1.14 BIOSYSTEMS DIAGNOSTICS 252
16.1.14.1 Business overview 252
16.1.14.2 Products offered 252
16.2 OTHER PLAYERS 253
16.2.1 DRUCKER DIAGNOSTICS 253
16.2.2 ACCUREX 254
16.2.3 STRECK 255
16.2.4 NEOMEDICA 256
16.2.5 EVERLIFE CPC 257
16.2.6 MERIL 258
16.2.7 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD. 259
16.2.8 PZ CORMAY S.A. 260
16.2.9 PIXCELL MEDICAL 262
16.2.10 RAYTO LIFE AND ANALYTICAL SCIENCES CO.,LTD. 263
16.2.11 ANALYTICON BIOTECHNOLOGIES GMBH 264
17 RESEARCH METHODOLOGY 265
17.1 INTRODUCTION 265
17.2 RESEARCH DATA 266
17.2.1 SECONDARY DATA 266
17.2.1.1 List of key secondary sources 267
17.2.1.2 Key data from secondary sources 268
17.2.2 PRIMARY RESEARCH 268
17.2.2.1 Key data from primary sources 269
17.2.2.2 Primary research objectives 269
17.2.2.3 Key industry insights 270
17.2.2.4 Breakdown of primaries 271
17.2.2.5 List of primary interview participants 271
17.3 MARKET SIZE ESTIMATION 272
17.3.1 BOTTOM-UP APPROACH 274
17.3.2 TOP-DOWN APPROACH 275
17.4 GROWTH FORECAST 276
17.5 DATA TRIANGULATION 278
17.6 MARKET SHARE ASSESSMENT 278
17.7 RESEARCH ASSUMPTIONS 279
17.8 RESEARCH LIMITATIONS 279
17.9 RISK ANALYSIS 280
18 APPENDIX 281
18.1 DISCUSSION GUIDE 281
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 288
18.3 CUSTOMIZATION OPTIONS 290
18.4 RELATED REPORTS 290
18.5 AUTHOR DETAILS 291

LIST OF TABLES

TABLE 1 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS 28
TABLE 2 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 44
TABLE 3 POTENTIAL BIOMARKERS DETECTABLE BY NEXT-GENERATION
HEMATOLOGY ANALYZERS 48
TABLE 4 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEEDS 50
TABLE 5 STRATEGIC FOCUS OF TIER-1/2/3 PLAYERS 51
TABLE 6 IMPACT OF PORTER’S FIVE FORCES ANALYSIS 52
TABLE 7 NORTH AMERICA: MACROECONOMIC OUTLOOK 54
TABLE 8 EUROPE: MACROECONOMIC OUTLOOK 55
TABLE 9 ASIA PACIFIC: MACROECONOMIC OUTLOOK 55
TABLE 10 LATIN AMERICA: MACROECONOMIC OUTLOOK 56
TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 56
TABLE 12 ROLE OF COMPANIES IN HEMATOLOGY ANALYZERS AND REAGENTS ECOSYSTEM 59
TABLE 13 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION,
2023–2025 (USD THOUSAND) 61
TABLE 14 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS,
BY PRICE RANGE, 2025 (USD THOUSAND) 62
TABLE 15 AVERAGE SELLING PRICE OF HEMATOLOGY REAGENTS & CONSUMABLES,
BY KEY PLAYER, 2025 (USD THOUSAND) 63
TABLE 16 IMPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 63
TABLE 17 EXPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 64
TABLE 18 LIST OF KEY CONFERENCES AND EVENTS, 2026–2027 65
TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY 70
TABLE 20 TARIFF-INDUCED PRICE INCREASES FOR HEALTHCARE PRODUCTS 71
TABLE 21 INNOVATIONS AND PATENT REGISTRATIONS, 2020–2024 76
TABLE 22 KEY COMPANIES IMPLEMENTING AI/GEN AI IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 80
TABLE 23 KEY APPLICATIONS AND CLINICAL OUTCOMES ENABLED BY HEMATOLOGY ANALYZERS 82
TABLE 24 NORTH AMERICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 83
TABLE 25 EUROPE: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 84
TABLE 26 ASIA PACIFIC: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 84
TABLE 27 LATIN AMERICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 85
TABLE 28 MIDDLE EAST & AFRICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 85
TABLE 29 IMPACT OF CLIA 2024 ON HEMATOLOGY ANALYZERS AND REAGENTS MARKET 87
TABLE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE (%) 92
TABLE 31 BUYING CRITERIA, BY PRODUCT & SERVICE 93
TABLE 32 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEED ANALYSIS,
BY END USER 95
TABLE 33 HEMATOLOGY ANALYZER SEGMENTATION, BY SYSTEM TYPE, PERFORMANCE,
AND PRICING 98
TABLE 34 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE,
2024–2031 (USD MILLION) 98
TABLE 35 LOW-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 99
TABLE 36 HIGH-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 101
TABLE 37 MID-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 102
TABLE 38 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE,
2024–2031 (USD MILLION) 104
TABLE 39 STANDALONE ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 105
TABLE 40 POINT-OF-CARE ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 106
TABLE 41 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 108
TABLE 42 HEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 109
TABLE 43 HEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 110
TABLE 44 HEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 110
TABLE 45 HEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 111
TABLE 46 HEMATOLOGY REAGENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 112
TABLE 47 HEMATOLOGY CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 113
TABLE 48 HEMATOLOGY CONTROLS & CALIBRATORS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 114
TABLE 49 HEMATOLOGY SLIDE STAINERS & MAKERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 115
TABLE 50 HEMATOLOGY INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 116
TABLE 51 HEMATOLOGY INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 116
TABLE 52 5-PART VS. 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS 117
TABLE 53 5-PART & 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 118
TABLE 54 3-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 55 POINT-OF-CARE & SEMI-AUTOMATED TESTING HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 120
TABLE 56 HEMATOLOGY SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 120
TABLE 57 HEMOSTASIS PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 121
TABLE 58 HEMOSTASIS PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 121
TABLE 59 HEMOSTASIS REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 60 HEMOSTASIS INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 123
TABLE 61 HEMOSTASIS SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 124
TABLE 62 IMMUNOHEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 124
TABLE 63 IMMUNOHEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 125
TABLE 64 IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 65 IMMUNOHEMATOLOGY INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 127
TABLE 66 IMMUNOHEMATOLOGY SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 127
TABLE 67 HAEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 129
TABLE 68 HEMORRHAGIC CONDITIONS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 130
TABLE 69 INFECTIOUS DISEASES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 131
TABLE 70 IMMUNE SYSTEM DISORDERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 71 BLOOD CANCER: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 133
TABLE 72 ANEMIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 134
TABLE 73 OTHER APPLICATIONS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 135
TABLE 74 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER,
2024–2031 (USD MILLION) 137
TABLE 75 COMMERCIAL SERVICE PROVIDERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 138
TABLE 76 HOSPITAL LABORATORIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 139
TABLE 77 GOVERNMENT REFERENCE LABORATORIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 78 RESEARCH & ACADEMIC INSTITUTES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 79 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 143
TABLE 80 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 81 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 145
TABLE 82 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 145
TABLE 83 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 146
TABLE 84 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 146
TABLE 85 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE,
2024–2031 (USD MILLION) 147
TABLE 86 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRICE RANGE, 2024–2031 (USD MILLION) 147
TABLE 87 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 148
TABLE 88 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY USAGE TYPE, 2024–2031 (USD MILLION) 148
TABLE 89 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 149
TABLE 90 US: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 150
TABLE 91 CANADA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 151
TABLE 92 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 93 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 152
TABLE 94 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 153
TABLE 95 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 153
TABLE 96 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 154
TABLE 97 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE,
2024–2031 (USD MILLION) 154
TABLE 98 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION) 154
TABLE 99 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 155
TABLE 100 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION) 155
TABLE 101 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION) 155
TABLE 102 GERMANY: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 156
TABLE 103 FRANCE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 157
TABLE 104 UK: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 158
TABLE 105 ITALY: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 159
TABLE 106 SPAIN: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 160
TABLE 107 REST OF EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 161
TABLE 108 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 109 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 163
TABLE 110 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 163
TABLE 111 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 164
TABLE 112 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 164
TABLE 113 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE,
2024–2031 (USD MILLION) 165
TABLE 114 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRICE RANGE, 2024–2031 (USD MILLION) 165
TABLE 115 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 166
TABLE 116 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY USAGE TYPE, 2024–2031 (USD MILLION) 166
TABLE 117 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 166
TABLE 118 CHINA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 167
TABLE 119 JAPAN: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 168
TABLE 120 INDIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 169
TABLE 121 AUSTRALIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 170
TABLE 122 SOUTH KOREA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 171
TABLE 123 REST OF ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 172
TABLE 124 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 125 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 173
TABLE 126 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 127 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 174
TABLE 128 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 174
TABLE 129 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE,
2024–2031 (USD MILLION) 175
TABLE 130 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE,
2024–2031 (USD MILLION) 175
TABLE 131 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY APPLICATION,
2024–2031 (USD MILLION) 176
TABLE 132 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY USAGE TYPE,
2024–2031 (USD MILLION) 176
TABLE 133 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY END USER,
2024–2031 (USD MILLION) 177
TABLE 134 BRAZIL: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 178
TABLE 135 MEXICO: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 178
TABLE 136 REST OF LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 179
TABLE 137 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 138 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 180
TABLE 139 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 180
TABLE 140 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 141 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 142 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE,
2024–2031 (USD MILLION) 182
TABLE 143 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRICE RANGE, 2024–2031 (USD MILLION) 182
TABLE 144 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 183
TABLE 145 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY USAGE TYPE, 2024–2031 (USD MILLION) 183
TABLE 146 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 184
TABLE 147 GCC COUNTRIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 184
TABLE 148 REST OF MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 185
TABLE 149 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022–MARCH 2026 187
TABLE 150 HEMATOLOGY ANALYZERS AND REAGENTS MARKET:
DEGREE OF COMPETITION, 2025 189
TABLE 151 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REGION FOOTPRINT 197
TABLE 152 HEMATOLOGY ANALYZERS AND REAGENTS MARKET:
PRODUCT & SERVICE FOOTPRINT 198
TABLE 153 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: APPLICATION FOOTPRINT 199
TABLE 154 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: END USER FOOTPRINT 200
TABLE 155 HEMATOLOGY ANALYZERS AND REAGENTS MARKET:
DETAILED LIST OF KEY STARTUPS/SMES 203
TABLE 156 HEMATOLOGY ANALYZERS AND REAGENTS MARKET:
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 204
TABLE 157 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 205
TABLE 158 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DEALS,
JANUARY 2022–MARCH 2026 206
TABLE 159 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: EXPANSIONS,
JANUARY 2022–MARCH 2026 206
TABLE 160 SYSMEX CORPORATION: COMPANY OVERVIEW 208
TABLE 161 SYSMEX CORPORATION: PRODUCTS OFFERED 209
TABLE 162 SYSMEX CORPORATION: DEALS, JANUARY 2022–MARCH 2026 211
TABLE 163 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2026 212
TABLE 164 ABBOTT: COMPANY OVERVIEW 214
TABLE 165 ABBOTT: PRODUCTS OFFERED 215
TABLE 166 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 216
TABLE 167 DANAHER CORPORATION: COMPANY OVERVIEW 218
TABLE 168 DANAHER CORPORATION: PRODUCTS OFFERED 219
TABLE 169 DANAHER CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025 220
TABLE 170 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 222
TABLE 171 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 223
TABLE 172 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022– MARCH 2026 225
TABLE 173 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022– MARCH 2026 225
TABLE 174 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 227
TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 228
TABLE 176 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 229
TABLE 177 DIATRON: COMPANY OVERVIEW 230
TABLE 178 DIATRON: PRODUCTS OFFERED 230
TABLE 179 DIATRON: EXPANSIONS, JANUARY 2022–MARCH 2026 231
TABLE 180 DREW SCIENTIFIC: COMPANY OVERVIEW 232
TABLE 181 DREW SCIENTIFIC: PRODUCTS OFFERED 232
TABLE 182 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 233
TABLE 183 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 234
TABLE 184 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–MARCH 2026 235
TABLE 185 HORIBA: COMPANY OVERVIEW 236
TABLE 186 HORIBA: PRODUCTS OFFERED 237
TABLE 187 HORIBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 239
TABLE 188 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW 240
TABLE 189 NIHON KOHDEN CORPORATION: PRODUCTS OFFERED 241
TABLE 190 NIHON KOHDEN CORPORATION: DEALS, JANUARY 2022–MARCH 2026 242
TABLE 191 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW 243
TABLE 192 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED 244
TABLE 193 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 245
TABLE 194 BOULE: COMPANY OVERVIEW 246
TABLE 195 BOULE: PRODUCTS OFFERED 247
TABLE 196 BOULE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026 248
TABLE 197 BOULE: DEALS, JANUARY 2022–MARCH 2026 248
TABLE 198 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 249
TABLE 199 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 250
TABLE 200 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–MARCH 2025 251
TABLE 201 BIOSYSTEMS DIAGNOSTICS: COMPANY OVERVIEW 252
TABLE 202 BIOSYSTEMS DIAGNOSTICS: PRODUCTS OFFERED 252
TABLE 203 DRUCKER DIAGNOSTICS: COMPANY OVERVIEW 253
TABLE 204 ACCUREX: COMPANY OVERVIEW 254
TABLE 205 STRECK: COMPANY OVERVIEW 255
TABLE 206 NEOMEDICA: COMPANY OVERVIEW 256
TABLE 207 EVERLIFE CPC: COMPANY OVERVIEW 257
TABLE 208 MERIL: COMPANY OVERVIEW 258
TABLE 209 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 259
TABLE 210 PZ CORMAY S.A.: COMPANY OVERVIEW 260
TABLE 211 PIXCELL MEDICAL: COMPANY OVERVIEW 262
TABLE 212 RAYTO LIFE AND ANALYTICAL SCIENCES CO.,LTD.: COMPANY OVERVIEW 263
TABLE 213 ANALYTICON BIOTECHNOLOGIES GMBH: COMPANY OVERVIEW 264
TABLE 214 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH ASSUMPTIONS 279
TABLE 215 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RISK ANALYSIS 280

LIST OF FIGURES

FIGURE 1 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SEGMENTATION AND REGIONAL SCOPE 27
FIGURE 2 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DURATION CONSIDERED 30
FIGURE 3 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SCENARIO 34
FIGURE 4 GLOBAL HEMATOLOGY ANALYZERS AND REAGENTS MARKET SIZE, 2024–2031 34
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET, 2022–2026 35
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF HEMATOLOGY ANALYZERS AND REAGENTS MARKET 36
FIGURE 7 HIGH-GROWTH SEGMENTS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET, 2026–2031 37
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET DURING FORECAST PERIOD 38
FIGURE 9 INCREASING HEALTHCARE INVESTMENTS AND AWARENESS ABOUT EARLY DISEASE DIAGNOSIS TO DRIVE HEMATOLOGY ANALYZERS AND
REAGENTS MARKET 39
FIGURE 10 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD 40
FIGURE 11 COMMERCIAL SERVICE PROVIDERS AND CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN ASIA PACIFIC IN 2025 41
FIGURE 12 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2026 TO 2031 42
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
FIGURE 14 PORTER’S FIVE FORCES ANALYSIS 52
FIGURE 15 HEMATOLOGY ANALYZERS AND REAGENTS VALUE CHAIN ANALYSIS 57
FIGURE 16 HEMATOLOGY ANALYZERS AND REAGENTS ECOSYSTEM ANALYSIS 58
FIGURE 17 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023–2025 61
FIGURE 18 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS,
BY PRICE RANGE, 2025 62
FIGURE 19 IMPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS FOR TOP FIVE COUNTRIES, 2021–2025 64
FIGURE 20 EXPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS FOR TOP FIVE COUNTRIES, 2021–2025 65
FIGURE 21 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS 66
FIGURE 22 INVESTMENT AND FUNDING SCENARIO, 2019–2023 67
FIGURE 23 NUMBER OF DEALS, BY KEY PLAYER, 2019–2023 67
FIGURE 24 DEAL VALUES, BY KEY PLAYER, 2019–2023 68
FIGURE 25 PATENTS APPLIED AND GRANTED, 2016–2025 75
FIGURE 26 KEY AI/GEN AI USE CASES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 79
FIGURE 27 HEMATOLOGY ANALYZER AND REAGENTS MARKET: DECISION-MAKING FACTORS 91
FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE 92
FIGURE 29 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 93
FIGURE 30 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEED ANALYSIS 96
FIGURE 31 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET SNAPSHOT 144
FIGURE 32 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET SNAPSHOT 162
FIGURE 33 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REVENUE ANALYSIS OF TOP FOUR PLAYERS, 2021−2025 188
FIGURE 34 MARKET SHARE ANALYSIS OF COMPANIES OFFERING HEMATOLOGY ANALYZERS AND REAGENTS, 2025 189
FIGURE 35 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RANKING OF
KEY PLAYERS, 2025 192
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 192
FIGURE 37 FINANCIAL METRICS (EV/EBITDA) 193
FIGURE 38 PRODUCT COMPARATIVE ANALYSIS 193
FIGURE 39 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 195
FIGURE 40 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY FOOTPRINT 196
FIGURE 41 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 202
FIGURE 42 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024) 209
FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 215
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 219
FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 223
FIGURE 46 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:
COMPANY SNAPSHOT (2025) 227
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 234
FIGURE 48 HORIBA: COMPANY SNAPSHOT (2025) 237
FIGURE 49 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2025) 241
FIGURE 50 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2024) 244
FIGURE 51 BOULE: COMPANY SNAPSHOT (2024) 247
FIGURE 52 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 250
FIGURE 53 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH DATA 265
FIGURE 54 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH DESIGN 266
FIGURE 55 DATA CAPTURED FROM SECONDARY SOURCES 268
FIGURE 56 PRIMARY SOURCES 269
FIGURE 57 CORE FINDINGS FROM INDUSTRY EXPERTS 270
FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 271
FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 271
FIGURE 60 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 273
FIGURE 61 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: BOTTOM-UP APPROACH 274
FIGURE 62 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SIZE ESTIMATION
(APPROACH 1) 275
FIGURE 63 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: TOP-DOWN APPROACH 276
FIGURE 64 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: MARKET SIZE ESTIMATION 277
FIGURE 65 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DATA TRIANGULATION 278

---

---